Аннотация:Vaccine Breakthrough Infections with SARS-CoV-2 VariantsTo the Editor: The article by Hacisuleyman et al. (published online on April 21) 1 reinforces concerns about SARS-CoV-2 variants and vaccine breakthrough.The authors describe two fully vaccinated women older than 50 years of age in whom subsequent vaccine breakthrough infection occurred with variants.The authors did not report on the measurement of SARS-CoV-2-specific T-cell responses.T-cell immunity is important in the control of SARS-CoV-2 2 and may be critical for potential cross-reactive protection against variants.SARS-CoV-2 messenger RNA (mRNA) vaccines generate weaker T-cell responses than other vaccine platforms. 3Although several mix-and-match vaccine studies are ongoing or planned, the effect of a vector boost of an mRNA vaccine prime on T-cell responses is currently unknown.Since Covid-19 vaccines vary with regard to immunogenicity and immune specificity, we would encourage consideration of a vaccine boost from a T-cell-skewed vaccine after mRNA vaccination to boost T-cell responses and potentially to reduce the chance of breakthrough infection through the generation of cross-protective T-cell immunity.The prevention of vaccine failure due to variants is a critical part of pandemic management.
